Browse institutions

… Medical Group, PC, Mid-Atlantic Permanente Research Institute, Marshfield Clinic Research Institute, and OptumInsight Life Sciences, but restrictions apply to the …

…ady yielded key advances. Most notably, the CLASI WG led to the FDA acknowledgement that CLASI 70 is a reasonable instrument for as…

…l p<0.05), while reducing time in range (β=−0.87%; p<0.05). The FDA showed that participants with long sleep (>9 hours/day) had ele…

…4;JCO 42:7047-7047. DOI:10.1200/JCO.2024.42.16_suppl.70472 U.S. FDA approves Bristol Myers Squibb’s 2. Breyanzi® as the first and o…

…al Oncology-Magnitude of Clinical Benefit Scale3 as well as the Common Sense Oncology initiative.4Scientifically, using an inferior control arm compromises the …

…applicable regulatory requirements including but not limited to FDA Regulations (21 CFR 50, 54, 56 and 812), Department of Health a…

…clinical AI tools face limited US Food and Drug Administration (FDA) oversight, leading to inadequate evaluation.2 Over half of 100…

… sources from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The framework covers: (i) uniform reporting; (ii) curate…

…rformed by the USA’s National Institutes of Health (NIH) or the National Cancer Institute. In the study of Zhou et al, of all classes of drugs, costs of …

…ency was the most under-reported (4/9 drug treatments). Between ClinicalTrials.gov and FAERS, 27 out of 36 irAEs showed low concordance (kappa sco…

…therapy (tx). A pan-tumor cutoff of 10 mutations (mt)/MB gained FDA approval of pembrolizumab although optimal cutoffs are not clea…

…nse prediction, and inclusion in immunotherapy clinical trials. Discovery Life Sciences (Discovery) leverages CAP/CLIA-certified FISH services with dee…